SCHEMBL1132844

SCHEMBL1132844

COc1cccnc1C(C)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.46
ACHE P22303 2/20 0.44
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
CYP2D6 P10635 1/20 0.40
HRH1 P35367 1/20 0.40
KCNH2 Q12809 1/20 0.40
LMNA P02545 2/20 0.40
AGTR1 P30556 1/20 0.40
CYP1A2 P05177 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
DYRK1A Q13627 1/20 0.39
TP53 P04637 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28825255 1.00 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL29808848 1.00 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL9963325 0.86 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL31082195 0.82 PLAU (0.35) PLAUACHECYP2D6HRH1KCNH2
SCHEMBL7758117 0.81 GRM5 (0.44) LMNAMEN1KMT2AGAAGRM5
SCHEMBL8429785 0.81 PLAU (0.42) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL30824545 0.81 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL6954493 0.81 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL31125653 0.81 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6
SCHEMBL27154590 0.81 PLAU (0.46) PLAUACHEPDGFRBPDGFRACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114934083-A Preparation method of high-purity (S) -1- (pyridine-2-yl) ethanol derivative 重庆张邦医药科技有限责任公司 2022-08-23 CN disclosed
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 PLAU 4257/4885ACHE 1195/4885PDGFRB 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.